[go: up one dir, main page]

AU2003295086A1 - Single chain antibodies produced in a transgenic mouse - Google Patents

Single chain antibodies produced in a transgenic mouse

Info

Publication number
AU2003295086A1
AU2003295086A1 AU2003295086A AU2003295086A AU2003295086A1 AU 2003295086 A1 AU2003295086 A1 AU 2003295086A1 AU 2003295086 A AU2003295086 A AU 2003295086A AU 2003295086 A AU2003295086 A AU 2003295086A AU 2003295086 A1 AU2003295086 A1 AU 2003295086A1
Authority
AU
Australia
Prior art keywords
single chain
chain antibodies
antibodies produced
transgenic mouse
transgenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003295086A
Other versions
AU2003295086A8 (en
Inventor
Marianne Bruggemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Babraham Institute
Original Assignee
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Institute filed Critical Babraham Institute
Publication of AU2003295086A8 publication Critical patent/AU2003295086A8/en
Publication of AU2003295086A1 publication Critical patent/AU2003295086A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/15Humanized animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/01Animal expressing industrially exogenous proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003295086A 2002-12-03 2003-12-03 Single chain antibodies produced in a transgenic mouse Abandoned AU2003295086A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0228210.1 2002-12-03
GB0228210A GB0228210D0 (en) 2002-12-03 2002-12-03 Single chain antibodies
PCT/GB2003/005274 WO2004049794A2 (en) 2002-12-03 2003-12-03 Single chain antibodies produced in a transgenic mouse

Publications (2)

Publication Number Publication Date
AU2003295086A8 AU2003295086A8 (en) 2004-06-23
AU2003295086A1 true AU2003295086A1 (en) 2004-06-23

Family

ID=9949000

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003295086A Abandoned AU2003295086A1 (en) 2002-12-03 2003-12-03 Single chain antibodies produced in a transgenic mouse

Country Status (3)

Country Link
AU (1) AU2003295086A1 (en)
GB (1) GB0228210D0 (en)
WO (1) WO2004049794A2 (en)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
SG188080A1 (en) 2004-07-22 2013-03-28 Univ Erasmus Medical Ct Binding molecules
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
EP1991580A2 (en) 2006-01-25 2008-11-19 Erasmus University Medical Center Rotterdam Generation of heavy-chain only antibodies in transgenic animals
GB0601511D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding Molecules 2
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
CA2673331A1 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
WO2012130874A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Bispecific anti-cxcr7 immunoglobulin single variable domains
GB0706628D0 (en) * 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
HUE037302T2 (en) 2007-06-01 2018-08-28 Open Monoclonal Tech Inc Preparations and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotypic antibodies
CN101970490A (en) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
CA2720013C (en) 2008-04-03 2016-02-16 Bart De Strooper Single domain antibodies capable of modulating bace activity
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
CN102056945A (en) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 Amino acid sequences directed against the Notch pathways and uses thereof
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
WO2009143472A2 (en) 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
PL2285408T3 (en) 2008-06-05 2019-05-31 Ablynx Nv Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
SG172176A1 (en) * 2008-12-18 2011-07-28 Univ Erasmus Medical Ct Non-human transgenic animals expressing humanised antibodies and use therof
JP2012512646A (en) 2008-12-19 2012-06-07 アブリンクス エン.ヴェー. Methods for generating immunoglobulin sequences
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
ES2894364T3 (en) 2009-10-22 2022-02-14 Univ Twente VHH for application in tissue repair, organ regeneration, organ replacement, and tissue engineering
PT2509409T (en) 2009-12-10 2016-09-29 Regeneron Pharma Mice that make heavy chain antibodies
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
MY172618A (en) 2010-08-02 2019-12-06 Regeneron Pharma Mice that make binding proteins comprising vl domains
HUE034017T2 (en) 2010-08-26 2018-01-29 Agrosavfe N V Compositions for seed treatment
EA202092589A3 (en) 2010-11-08 2021-06-30 Аблинкс Н.В. CXCR2-BINDING POLYPEPTIDES
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
EP3345919A1 (en) 2011-06-21 2018-07-11 VIB vzw Binding domains directed against gpcr:g protein complexes and uses derived thereof
SG10201606158TA (en) 2011-08-05 2016-09-29 Regeneron Pharma Humanized universal light chain mice
US10246509B2 (en) 2011-10-17 2019-04-02 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
RU2664181C2 (en) 2011-12-20 2018-08-15 Регенерон Фармасьютикалз, Инк. Humanised light chain mice
EP2617732A1 (en) 2012-01-19 2013-07-24 Vib Vzw Tools and methods for expression of membrane proteins
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2855526B1 (en) 2012-05-24 2018-11-07 VIB vzw Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages
NZ703689A (en) 2012-06-12 2016-05-27 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
EP2951201B1 (en) 2013-01-30 2017-10-18 VIB vzw Novel chimeric polypeptides for screening and drug discovery purposes
DK2953973T3 (en) 2013-02-05 2019-08-12 Vib Vzw MUSCARINE ACETYL CHOLINE RECEPTOR BINDERS AND APPLICATIONS THEREOF
PL2840892T3 (en) 2013-02-20 2018-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
CA2906259C (en) 2013-03-15 2022-12-06 Vib Vzw Anti-mmr single variable domains for prognosis and monitoring of cardiovascular diseases
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
EP3099707B1 (en) 2014-01-30 2021-12-29 Vib Vzw Opioid receptor binding agents and uses thereof
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
RU2016141123A (en) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. VL ANTIGEN-BINDING PROTEINS MANIFESTING VARIOUS BINDING CHARACTERISTICS
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
EP3998281A1 (en) 2016-02-05 2022-05-18 Orionis Biosciences BV Cd8 binding agents
CA3016849A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
US11186641B2 (en) 2016-03-17 2021-11-30 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
SG11201810331YA (en) 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single chain variable fragment cd3 binding proteins
MX2018014228A (en) 2016-05-20 2019-08-12 Harpoon Therapeutics Inc SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN.
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
EP3544997A4 (en) 2016-11-23 2020-07-01 Harpoon Therapeutics, Inc. PROSTATE-SPECIFIC MEMBRANE ANTI-BINDING PROTEINS
AU2017363302A1 (en) 2016-11-23 2019-06-27 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
KR102777514B1 (en) 2017-01-19 2025-03-06 옴니에이비 오퍼레이션스, 인코포레이티드 Human antibodies of transgenic rodent origin with multiple heavy chain immunoglobulin loci
MX2019009255A (en) 2017-02-06 2019-11-05 Orionis Biosciences Nv Targeted chimeric proteins and uses thereof.
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
JP7090347B2 (en) 2017-05-12 2022-06-24 ハープーン セラピューティクス,インク. Mesothelin-binding protein
KR20200026810A (en) 2017-05-12 2020-03-11 하푼 테라퓨틱스, 인크. MSLN targeting trispecific proteins and methods of use
WO2018222587A1 (en) 2017-05-30 2018-12-06 The Regents Of The University Of California NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. Chimeric antibody immune effctor cell engagers and methods of use thereof
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
EP4435007A3 (en) 2017-10-13 2024-12-25 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
US12168688B2 (en) 2017-12-28 2024-12-17 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against PD-L1
TWI802633B (en) 2018-01-15 2023-05-21 大陸商南京傳奇生物科技有限公司 Single-domain antibodies and variants thereof against pd-1
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
US11896643B2 (en) 2018-02-05 2024-02-13 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
KR20200138720A (en) 2018-03-30 2020-12-10 난징 레전드 바이오테크 씨오., 엘티디. Single-domain antibodies to LAG-3 and uses thereof
CN117442717A (en) 2018-06-01 2024-01-26 大有华夏生物医药集团有限公司 Compositions for treating diseases or conditions and uses thereof
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
EP3850013A4 (en) 2018-09-10 2022-10-05 Nanjing Legend Biotech Co., Ltd. SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
JP7538130B2 (en) 2019-01-23 2024-08-21 タユー ファシャ バイオテック メディカル グループ カンパニー, リミテッド Anti-PD-L1 diabodies and uses thereof
CA3140430A1 (en) 2019-05-14 2020-11-19 Harpoon Therapeutics, Inc. Epcam binding proteins and methods of use
CN110818795B (en) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 anti-TIGIT antibodies and methods of use
CN115768463A (en) 2020-02-21 2023-03-07 哈普恩治疗公司 FLT 3-binding proteins and methods of use
JP2023516941A (en) 2020-02-28 2023-04-21 上海復宏漢霖生物技術股▲フン▼有限公司 Anti-CD137 constructs, multispecific antibodies and uses thereof
KR20220148209A (en) 2020-02-28 2022-11-04 상하이 헨리우스 바이오테크, 인크. Anti-CD137 constructs and uses thereof
CN116529260A (en) 2020-06-02 2023-08-01 当康生物技术有限责任公司 anti-CD 93 constructs and uses thereof
MX2022015376A (en) 2020-06-02 2023-04-14 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof.
EP4168433A4 (en) 2020-06-17 2024-07-17 Janssen Biotech, Inc. MATERIALS AND METHODS FOR THE MANUFACTURE OF PLURIPOTENT STEM CELLS
EP4188550A1 (en) 2020-07-29 2023-06-07 Dynamicure Biotechnology LLC Anti-cd93 constructs and uses thereof
WO2022156908A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method for preparing a lyophilized composition
WO2022156907A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Method and kit for labeling a biomolecule with one or more detectable labels, including a radiolabel
WO2022157373A1 (en) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Compositions and kits for in vivo imaging of cardiac sarcoidosis
KR20220118961A (en) 2021-02-19 2022-08-26 (주)샤페론 Single domain antibodies against CD47 and use thereof
AU2022222423A1 (en) 2021-02-19 2023-09-28 Shaperon Inc. Single domain antibody against pd-l1 and use thereof
CN116917322A (en) 2021-02-19 2023-10-20 沙裴隆有限公司 Bispecific single domain antibodies against PD-L1 and CD47 and uses thereof
CN117321076A (en) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 Single domain antibodies neutralizing SARS-CoV-2
TW202302646A (en) 2021-03-05 2023-01-16 美商當康生物科技有限公司 Anti-vista constructs and uses thereof
US20240150466A1 (en) 2021-03-25 2024-05-09 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
US20230174651A1 (en) 2021-06-23 2023-06-08 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
EP4412663A1 (en) 2021-10-05 2024-08-14 Vrije Universiteit Brussel Fluorescently labeled immunoglobulin single variable domains
CA3240585A1 (en) 2021-12-17 2023-06-22 Wenfeng Xu Anti-ox40 antibodies, multispecific antibodies and methods of use
CN118574849A (en) 2021-12-17 2024-08-30 上海复宏汉霖生物技术股份有限公司 Anti-OX 40 antibodies and methods of use
KR20240163119A (en) 2022-03-25 2024-11-18 상하이 헨리우스 바이오테크, 인크. Anti-MSLN antibodies and methods of use
US20250188492A1 (en) 2022-07-22 2025-06-12 Janssen Biotech, Inc. Enhanced Transfer of Genetic Instructions to Effector Immune Cells
CN120077071A (en) 2022-09-07 2025-05-30 当康生物技术有限责任公司 Anti-VISTA constructs and their uses
EP4349374A1 (en) 2022-10-05 2024-04-10 Vrije Universiteit Brussel Anti-urokinase plasminogen activator receptor immunoglobulin single variable domains
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
WO2025045250A1 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Anti-human factor d antibody constructs and uses thereof
WO2025088085A1 (en) 2023-10-26 2025-05-01 Abscint Nv Image guided biopsy of her2 positive lesions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110029D0 (en) * 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus

Also Published As

Publication number Publication date
WO2004049794A2 (en) 2004-06-17
WO2004049794A3 (en) 2004-12-02
AU2003295086A8 (en) 2004-06-23
GB0228210D0 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
AU2003295086A1 (en) Single chain antibodies produced in a transgenic mouse
AU2003217912A8 (en) Antibody optimization
AU2003229638A1 (en) Plane chain strand comprising a chain lock link
AU2003295148A1 (en) A combustion device
AUPS114102A0 (en) A turn buckle
AU2003208404A1 (en) A couplig
AU2002953172A0 (en) A Cladding Element
GB2404355B (en) A sawmill
AU2003248999A1 (en) A case
AU2003246545A1 (en) Problem solving by a cad program
AU2003211128A1 (en) Transgenic production in saliva
AU2002100695A4 (en) A mat
EP1541588A4 (en) Single chain antibody and utilization thereof
AU2003278554A1 (en) A shellfish dredge
AUPS336702A0 (en) A handrail
AU2003100320A4 (en) A method for carrying out a design project
AU148628S (en) A chain
AU2002953337A0 (en) A conveyor
AU2002953331A0 (en) A conveyor
AU2003264173A1 (en) A zip
AUPR998402A0 (en) A reconfigurable interface
AU150852S (en) A wedding adornment
AU2003906367A0 (en) A Conveyor
AU2002952437A0 (en) A saddle
AUPS170602A0 (en) A luminaire

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase